A cross-sectional study of the prevalence and associations of iron deficiency in a cohort of patients with chronic obstructive pulmonary disease

BMJ Open

Volumn 5, Issue 7, 2015, Pages

  Nickol, Annabel H ^a,b   Frise, Matthew C ^b   Cheng, Hung Yuan ^b   McGahey, Anne ^a   McFadyen, Bethan M ^a   Harris Wright, Tara ^a   Bart, Nicole K ^b   Curtis, M Kate ^b   Khandwala, Shivani ^c   O'Neill, David P ^b   Pollard, Karen A ^b   Hardinge, F Maxine ^a   Rahman, Najib M ^a   Armitage, Andrew E ^c   Dorrington, Keith L ^b   Drakesmith, Hal ^c   Ratcliffe, Peter J ^d   Robbins, Peter A ^a,b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FERRITIN; IRON; TRANSFERRIN; TRANSFERRIN RECEPTOR; HEMOGLOBIN; HEPCIDIN;

ADULT; ARTERIAL OXYGEN SATURATION; ARTICLE; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROL GROUP; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMOGLOBIN DETERMINATION; HUMAN; HYPOXEMIA; IRON DEFICIENCY; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; OXIMETRY; PHENOTYPE; PREVALENCE; SELF REPORT; SEX; TASK PERFORMANCE; AGED; COMPLICATION; DEFICIENCY; HYPOXIA; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VITAL CAPACITY;

AGED; BIOMARKERS; C-REACTIVE PROTEIN; CROSS-SECTIONAL STUDIES; EXERCISE TOLERANCE; FEMALE; FERRITINS; FORCED EXPIRATORY VOLUME; HEMOGLOBINS; HEPCIDINS; HUMANS; HYPOXIA; IRON; MALE; PNEUMONIA; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VITAL CAPACITY;

EID: 84937220365     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2015-007911     Document Type: Article

References (48)

1. Friedmann B, Weller E, Mairbaurl H, et al. Effects of iron repletion on blood volume and performance capacity in young athletes. Med Sci Sports Exerc 2001;33:741-6.
2. Murray-Kolb LE. Iron status and neuropsychological consequences in women of reproductive age: what do we know and where are we headed? J Nutr 2011;141:747S-55S.
3. Klip IT, Comin-Colet J, Voors AA, et al. Iron deficiency in chronic heart failure: an international pooled analysis. Am Heart J 2013;165:575-82.
4. Anker SD, Comin Colet J, Filippatos G, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48.
5. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657-68.
6. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol 2004;5:343-54.
7. Robinson JC, Graham BB, Rouault TC, et al. The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension. Am J Respir Cell Mol Biol 2014;51:721-9.
8. Smith TG, Balanos GM, Croft QP, et al. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 2008;586(Pt 24):5999-6005.
9. Smith TG, Talbot NP, Privat C, et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: two randomized controlled trials. JAMA 2009;302:1444-50.
10. Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. Int J Chron Obstruct Pulmon Dis 2011;6:199-208.
11. Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J 2008;32:1371-85.
12. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012;338:768-72.
13. Goodnough LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010;116:4754-61.
14. Allen J, Backstrom KR, Cooper JA, et al. Measurement of soluble transferrin receptor in serum of healthy adults. Clin Chem 1998;44:35-9.
15. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
16. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68.
17. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-7.
18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70.
19. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.
20. Singh SJ, Morgan MD, Scott S, et al. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992;47:1019-24.
21. Cavill I. Iron status as measured by serum ferritin: the marker and its limitations. Am J Kidney Dis 1999;34(4 Suppl 2):S12-17.
22. Cook JD, Skikne BS. Serum ferritin: a possible model for the assessment of nutrient stores. Am J Clin Nutr 1982;35(5 Suppl): 1180-5.
23. Bainton DF, Finch CA. The diagnosis of iron deficiency anemia. Am J Med 1964;37:62-70.
24. Weinstein DA, Roy CN, Fleming MD, et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002;100:3776-81.
25. Fielding J, Zorab PA. Polycythaemia and iron deficiency in pulmonary "emphysema". Lancet 1964;2:284-6.
26. Soon E, Treacy CM, Toshner MR, et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax 2011;66:326-32.
27. Ruiter G, Lankhorst S, Boonstra A, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J 2011;37:1386-91.
28. Ruiter G, Lanser IJ, de Man FS, et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology 2014;53:285-92.
29. Rhodes CJ, Howard LS, Busbridge M, et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol 2011;58:300-9.
30. Brigham EP, McCormack MC, Takemoto CM, et al. Iron status is associated with asthma and lung function in US women. PLoS ONE 2015;10:e0117545.
31. Howard LS, Watson GM, Wharton J, et al. Supplementation of iron in pulmonary hypertension: rationale and design of a phase II clinical trial in idiopathic pulmonary arterial hypertension. Pulm Circ 2013;3:100-7.
32. Viethen T, Gerhardt F, Dumitrescu D, et al. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study. Int J Cardiol 2014;175:233-9.
33. Fischer R, Simmerlein R, Huber RM, et al. Lung disease severity, chronic inflammation, iron deficiency, and erythropoietin response in adults with cystic fibrosis. Pediatr Pulmonol 2007;42:1193-7.
34. Pond MN, Morton AM, Conway SP. Functional iron deficiency in adults with cystic fibrosis. Respir Med 1996;90:409-13.
35. Hoo ZH, Wildman MJ. Intravenous iron among cystic fibrosis patients. J Cyst Fibros 2012;11:560-2.
36. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortalityrelated factors after hospitalization for acute exacerbation of COPD. Chest 2003;124:459-67.
37. Tanabe N, Muro S, Hirai T, et al. Impact of exacerbations on emphysema progression in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011;183:1653-9.
38. Halpin DM, Decramer M, Celli B, et al. Exacerbation frequency and course of COPD. Int J Chron Obstruct Pulmon Dis 2012;7:653-61.
39. Singh SJ, Morgan MD, Hardman AE, et al. Comparison of oxygen uptake during a conventional treadmill test and the shuttle walking test in chronic airflow limitation. Eur Respir J 1994;7:2016-20.
40. Green DJ, Watts K, Rankin S, et al. A comparison of the shuttle and6 minute walking tests with measured peak oxygen consumption in patients with heart failure. J Sci Med Sport 2001;4:292-300.
41. Singh SJ, Jones PW, Evans R, et al. Minimum clinically important improvement for the incremental shuttle walking test. Thorax 2008;63:775-7.
42. Ringbaek T, Martinez G, Brondum E, et al. Shuttle walking test as predictor of survival in chronic obstructive pulmonary disease patients enrolled in a rehabilitation program. J Cardiopulm Rehabil Prev 2010;30:409-14.
43. Schneckenpointner R, Jorres RA, Meidenbauer N, et al. The clinical significance of anaemia and disturbed iron homeostasis in chronic respiratory failure. Int J Clin Pract 2014;68:130-8.
44. Silverberg DS, Mor R, Weu MT, et al. Anemia and iron deficiency in COPD patients: prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med 2014;14:24.
45. Portillo K, Martinez-Rivera C, Ruiz-Manzano J. Anaemia in chronic obstructive pulmonary disease. Does it really matter? Int J Clin Pract 2013;67:558-65.
46. Martinez-Rivera C, Portillo K, Munoz-Ferrer A, et al. Anemia is a mortality predictor in hospitalized patients for COPD exacerbation. COPD 2012;9:243-50.
47. Boutou AK, Karrar S, Hopkinson NS, et al. Anemia and survival in chronic obstructive pulmonary disease: a dichotomous rather than a continuous predictor. Respiration 2013;85:126-31.
48. Martinez FJ, Foster G, Curtis JL, et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 2006;173:1326-34.